File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Synthetic KL4 peptide as new carrier of siRNA therapeutics for pulmonary delivery

TitleSynthetic KL4 peptide as new carrier of siRNA therapeutics for pulmonary delivery
Authors
Issue Date2017
PublisherMary Ann Liebert, Inc. Publishers. The Journal's web site is located at http://www.liebertpub.com/products/product.aspx?pid=24
Citation
The 27th Drug Delivery to the Lungs (DDL27) Conference, Edinburgh, Scotland, UK, 7-9 December 2016. In Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2017, v. 30 n. 4, p. A-11, abstract no. 33 How to Cite?
AbstractSmall interfering RNA (siRNA) has great potential for the treatment of various respiratory diseases through RNA interference (RNAi), but their clinical application is hindered by the lack of a safe and effective pulmonary delivery system. KL4 peptide is a synthetic amphipathic peptide that was previously developed to mimic the function of pulmonary surfactant protein B (SP-B). Its potential as siRNA carrier for pulmonary delivery was examined in this study. The cationic KL4 peptide was able to bind with siRNA to form complexes at 15:1 ratio (peptide to siRNA weight ratio) or above. It also mediated efficient gene silencing on lung epithelial cells, with 20:1 ratio as the optimal ratio for siRNA transfection. Furthermore, the KL4/siRNA complexes were not toxic at concentrations used for transfection in vitro. The study shows that KL4 peptide appears to be a promising candidate for siRNA delivery. Further investigation on animal study and work on aerosol formulation are required to develop KL4 peptide as siRNA carrier for clinical application.
DescriptionPoster Presentation
Persistent Identifierhttp://hdl.handle.net/10722/245641
ISSN
2017 Impact Factor: 2.927
2015 SCImago Journal Rankings: 1.091

 

DC FieldValueLanguage
dc.contributor.authorQiu, Y-
dc.contributor.authorChow, MYT-
dc.contributor.authorLam, JKW-
dc.date.accessioned2017-09-18T02:14:18Z-
dc.date.available2017-09-18T02:14:18Z-
dc.date.issued2017-
dc.identifier.citationThe 27th Drug Delivery to the Lungs (DDL27) Conference, Edinburgh, Scotland, UK, 7-9 December 2016. In Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2017, v. 30 n. 4, p. A-11, abstract no. 33-
dc.identifier.issn1941-2711-
dc.identifier.urihttp://hdl.handle.net/10722/245641-
dc.descriptionPoster Presentation-
dc.description.abstractSmall interfering RNA (siRNA) has great potential for the treatment of various respiratory diseases through RNA interference (RNAi), but their clinical application is hindered by the lack of a safe and effective pulmonary delivery system. KL4 peptide is a synthetic amphipathic peptide that was previously developed to mimic the function of pulmonary surfactant protein B (SP-B). Its potential as siRNA carrier for pulmonary delivery was examined in this study. The cationic KL4 peptide was able to bind with siRNA to form complexes at 15:1 ratio (peptide to siRNA weight ratio) or above. It also mediated efficient gene silencing on lung epithelial cells, with 20:1 ratio as the optimal ratio for siRNA transfection. Furthermore, the KL4/siRNA complexes were not toxic at concentrations used for transfection in vitro. The study shows that KL4 peptide appears to be a promising candidate for siRNA delivery. Further investigation on animal study and work on aerosol formulation are required to develop KL4 peptide as siRNA carrier for clinical application.-
dc.languageeng-
dc.publisherMary Ann Liebert, Inc. Publishers. The Journal's web site is located at http://www.liebertpub.com/products/product.aspx?pid=24-
dc.relation.ispartofJournal of Aerosol Medicine and Pulmonary Drug Delivery-
dc.rightsJournal of Aerosol Medicine and Pulmonary Drug Delivery. Copyright © Mary Ann Liebert, Inc. Publishers.-
dc.rightsFinal publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/10.1089/jamp.2017.ab02.abstracts-
dc.titleSynthetic KL4 peptide as new carrier of siRNA therapeutics for pulmonary delivery-
dc.typeConference_Paper-
dc.identifier.emailLam, JKW: jkwlam@hku.hk-
dc.identifier.authorityLam, JKW=rp01346-
dc.identifier.hkuros277117-
dc.identifier.volume30-
dc.identifier.issue4-
dc.identifier.spageA-11-
dc.identifier.epageA-11-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats